TFS Capital’s Evoke Pharma EVOK Stock Holding History

TFS Capital’s Portfolio EVOK Stock Details EVOK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q2	–	Sell	-73	Closed	-$88K	–	1186
2014 Q1	$88K	Sell	73 -29	-28%	-$41.4K	0.01%	1288
2013 Q4	$110K	Buy	+102	New	+$146K	0.01%	1388

Other funds holding EVOK

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Sophrosyne Capital New York $11.5M AUM 17.82% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Zurich, Switzerland $136B AUM 16.36% 1-Year Est. Return

BIM

BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

TFS Capital's EVOK Position: Q2 2014 in Review

TFS Capital sold out of Evoke Pharma (EVOK) in Q2 2014, closing a stake of 73 shares — an estimated $88K sold.

TFS Capital first reported a position in EVOK in Q4 2013 and held it in 2 quarters. The position peaked at $110K in Q4 2013. 10 funds tracked by Wall St. Rank hold EVOK as of Q2 2014.

TFS Capital reported no remaining Evoke Pharma position as of Q2 2014 after selling out during the quarter.
TFS Capital sold 73 Evoke Pharma shares in Q2 2014, an estimated $88K.
TFS Capital first reported a position in Evoke Pharma in Q4 2013 and held it in 2 quarters.
TFS Capital's Evoke Pharma position peaked at $110K in Q4 2013.
10 funds tracked by Wall St. Rank held Evoke Pharma as of Q2 2014.

Based on TFS Capital's 13F filing for Q2 2014, filed 21 Jul 2014.